<DOC>
	<DOCNO>NCT02869035</DOCNO>
	<brief_summary>Major Depressive Disorder ( MDD ) one severe frequently occur brain disorder worldwide . It link serotonergic dysfunction , sexual dysfunction , vulnerability stress neuro-inflammation . However , time etiological understanding limit . Most antidepressant act serotonin ( 5- HT ) system , yet 30-50 % patient MDD respond successfully 5-HT act drug . Recent experimental model group suggest cerebral 5-HT level vivo indexed molecular brain image 5-HT 4 receptor ( 5-HT4R ) novel Positron Emission Tomography ( PET ) ligand ( 11C-SB207145 ) . Also , human study confirm cerebral synaptic 5-HT inversely related 5-HT4R binding technique thus use investigate role 5-HT tone brain MDD differential response standard antidepressant treatment . By use multimodal neuroimaging technology , aim determine status 5-HT system prior either successful fail neuropharmacological intervention non-randomized longitudinal open clinical trial . 100 untreated patient moderate severe MDD include . Data collection various neurobiological domain ( i.e , 5-HT4R PET imaging , Magnetic Resonance Imaging ( MRI ) , functional MRI ( fMRI ) , electroencephalogram ( EEG ) , psychometrics , neuropsychological test , peripheral biomarkers ) conduct , 12 week antidepressant treatment . The objective identify predictor pharmacological antidepressant treatment response depress individual 8 week antidepressant treatment .</brief_summary>
	<brief_title>Treatment Outcome Major Depressive Disorder</brief_title>
	<detailed_description>Study population study program : Patients recruit unique new central referral site `` depression package '' The Mental Health Services Capital Region Denmark . 100 patient MDD , 18-65 year age , moderate severe single recurrent episode MDD ( Hamilton 17 item ( HAMD-17 ) score &gt; 17 ) recruit portal . All diagnosis confirm specialist psychiatry . Before initiation pharmacological antidepressant treatment escitalopram , patient receive baseline examination follow : 1 ) 5-HT4R image 11C-SB207145 PET-scan , 2 ) EEG examination , 3 ) structural MRI , 4 ) functional MRI , 5 ) neuropsychological testing , 6 ) peripheral marker immune-active cell response , oxidative stress , cortisol-levels , RNA , genotypes epigenetic factor measure urine , saliva peripheral blood baseline across study period . Repeated measure across study period include : 7 ) psychometrics use self-reported questionnaire cover trait state , include mental distress relate depression psychopathology , 8 ) neuropsychological examination well 9 ) clinical follow-up interview base rating mental status . Patients treat escitalopram flexible dos 10-20 mg/day adjust depend effect side effect , participate clinical follow-up session week 1 , 2 , 4 8 . Patients response escitalopram 4 week shift secondary pharmacological treatment ( duloxetine ) . A final visit determine longer-term clinical outcome perform week 12 . Compliance , side-effects antidepressant treatment , depressive symptom monitor follow-up session . The Hamilton 6 item ( HAMD-6 ) subscale recently show sensitive antidepressant response ( Ã˜stergaard et al ) , use identify treatment response patient . Patients &gt; 50 % reduction HAMD-6 4 week define early responder , additional &lt; 5 point HAMD-6 scale 8 week consider remission . Patients &lt; 50 % reduction HAMD-6 full intervention consider non-responders . The assessment program include brain imaging PET 11C-SB207145 conduct drug intervention initiate , depend treatment outcome , 8 week antidepressant treatment 20 patient remission ( remitters ) 20 non-responding patient ( non-responders ) . Healthy control : From previous study conduct Neurobiological Research Unit , access brain image data baseline PET-SB207145 brain image among healthy control well associate biobank store blood specimen . During trial , additional healthy control include receive baseline examination repeat neuropsychological test 12 week . Hypotheses : 1 . 5-HT4R binding ( imaged 11C-SB207145 PET ) treatment predict antidepressant treatment outcome ( remission v non-response ) depress patient ; high bind baseline hypothesize associate well treatment outcome . Likewise , secondary , 5-HT4R binding ( imaged 11C-SB207145 PET ) treatment expect associated magnitude change baseline Hamilton score ( HAMD-6 ) 8 week . 2 . Remitters display great reduction 5-HT4R binding ( imaged 11C-SB207145 PET ) antidepressant treatment relative non-responders . 3 . Patients MDD high 5-HT4R binding ( imaged 11C-SB207145 PET ) relative healthy control . 4 . High amygdala reactivity `` emotional face '' fMRI paradigm treatment predict remission response antidepressant treatment . 5 . Amygdala response exposure negative emotional face ( fear anger ) cerebral 5-HT4R binding expect associated , cross-sectional comparison treatment regard longitudinal change ( change baseline ) . 6 . In rest state fMRI ( rsfMRI ) , expect change baseline functional network center around dorsomedial prefrontal cortex network center around anterior cingulate cortex posterior cingulate cortex ( default mode network ) respectively predict treatment outcome . 7 . Low activity brain network engage reward processing ( assessed fMRI ) predict antidepressant treatment response ( i.e . positive association low activity remitter- relative non-responder group ) cross-sectional comparison treatment regard longitudinal change ( change baseline ) . 8 . We expect reduce evoked gamma-activity measure EEG `` Event-related-potentials '' ( ERP ) MDD patient compare control . 9 . Using EEG/ERP , expect reduce alpha theta cordance high theta band activity among remitters measure baseline . 10 . Higher level systemic inflammation predict poor cognitive function baseline , poor antidepressant treatment outcome . 11 . A blunted cortisol awaken response ( CAR ) baseline predict positive antidepressant treatment outcome . 12 . Restored HPA-axis dynamic ( increased CAR compare baseline ) week 8 associate positive treatment outcome . 13 . There significant association functional network find EEG fMRI , baseline contrast remitters non-responders 8 week . 14 . Hippocampal volume predict treatment outcome . 15 . Patients low 5-HT4R binding ( imaged 11C-SB207145 PET ) baseline treatment low libido relative patient high binding . 16 . Patients respond antidepressant treatment pronounce change 5-HT4R binding ( imaged 11C-SB207145 ) experience large degree sexual side-effects ; i.e. , magnitude 5-HT4R binding change baseline positively associate degree sexual side-effects . 17 . Childhood abuse ( define composite measure early life stress questionnaire ) anxious depression ( define anxiety/somatization factor score HAMD-17 &gt; 7 ) predicts poor antidepressant treatment outcome . 18 . We expect urinary marker oxidatively generate DNA/RNA damage increase responder non-responders . 19 . With exploratory approach possible identify set predictor antidepressant treatment outcome . This explorative analysis include genetics , epigenetics , peripheral central neurobiological characteristic , neuropsychology test outcome , psychometry include self-reported mental distress , cross-sectional baseline longitudinal measure . Ethical Aspects : The study protocol complies Declaration Helsinki II approval relevant authority obtain initiation . All human volunteer receive oral write information give study provide write informed consent enrolment . The trial monitor Good Clinical Practise unit relevant domain .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Moderate severe depression Age 1865 year No previous antidepressant treatment last 2 month Informed sign consent More one previous attempt antidepressant drug Duration current depression 2 year Current previous psychiatric severe comorbidity Acute suicidal ideation Psychotic Previous nonresponse Selective Serotonin Reuptake Inhibitor ( SSRI ) Contraindication SSRI treatment More suitable treatment alternative antidepressive drug . Severe somatic comorbidity Somatic medicine influence trial Contraindications MRscanning Previous exposure radioactivity &gt; 10 milli sievert ( mSv ) within last year Alcohol drug abuse Previous severe head trauma Pregnancy Breastfeeding Insufficient Danish skill</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PET</keyword>
	<keyword>Serotonin</keyword>
	<keyword>5-HT4R</keyword>
	<keyword>MRI</keyword>
	<keyword>fMRI</keyword>
	<keyword>EEG</keyword>
	<keyword>Cortisol awaken response</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Mental health</keyword>
	<keyword>Prediction treatment response</keyword>
	<keyword>Inflammation</keyword>
	<keyword>5-HTTLPR</keyword>
	<keyword>Brain imaging</keyword>
	<keyword>Early life stress</keyword>
	<keyword>Selective Serotonin Reuptake Inhibitor</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Psychometrics</keyword>
	<keyword>Moderate depression</keyword>
	<keyword>Severe depression</keyword>
	<keyword>ERP</keyword>
	<keyword>rsfMRI</keyword>
	<keyword>11C-SB207145</keyword>
	<keyword>Sexual function</keyword>
	<keyword>MDD</keyword>
	<keyword>Affective cognition</keyword>
	<keyword>Cold cognition</keyword>
	<keyword>Social cognition</keyword>
	<keyword>Anxiety</keyword>
</DOC>